Abstract
In early, androgen dependent stages of prostate cancer, androgen withdrawal, the major course of therapy in prostate cancer, leads to a rapid regression of the tumor as a result of apoptosis. However, prostate cancer invariably progresses to an androgen independent and apoptosis resistant stage for which no curative treatment is available. The molecular details of regression upon androgen withdrawal and progression to a resistant state are largely unknown. Here we show that c-Jun N-terminal Kinase (JNK) is activated strongly and in a sustained fashion by 12-O-tetradecanoylphorbol 13-acetate (TPA) and thapsigargin (TG), two agents which were previously shown to lead to apoptosis in the androgen responsive prostate cancer cell line LNCaP. The time course of JNK induction by both compounds correlated very well with the onset and progression of apoptosis in LNCaP cells. Inhibition of either ERK or p38 pathways did not affect TPA-induced cell death. In the androgen-independent prostate cancer cell lines DU-145 and PC-3, and in the cervical carcinoma cell line HeLaS3, TPA did not lead to apoptosis and there were no significant changes in JNK activity upon TPA treatment. The failure of TPA to induce JNK activity in PC-3, DU-145, and HelaS3 cells was not due to a general defect in JNK signaling since ultraviolet (UV) irradiation dramatically increased JNK activity in all four cell lines. Specific inhibition of JNK by expression of the JNK Inhibitory Protein (JIP) dramatically inhibited both TPA- and TG-induced apoptosis. Furthermore, apoptosis induced by both agents was completely blocked by ectopic expression of the baculovirus caspase-inhibitor P35. Surprisingly, ZVAD-fmk, a cell-permeable fluoromethylketone inhibitor of caspases, had no effect on TPA-induced apoptosis, whereas it completely inhibited TG-induced cell death; JNK activity was not affected in either case. This indicates that ZVAD-fmk does not inhibit some of the caspases involved in TPA-induced apoptosis, and that despite the common requirement of JNK activation, TPA- and TG-induced cell death are mechanistically different. Furthermore, it also suggests that JNK is either upstream or independent of caspases in LNCaP cells. Collectively, these results indicate that apoptosis in LNCaP cells requires a sustained increase in JNK activity and caspase activation; components of these signaling pathways may be defective in the androgen independent prostate cancer cell lines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig3_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig4_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig5_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig6_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1205167/MediaObjects/41388_2002_Article_BF1205167_Fig7_HTML.jpg)
Similar content being viewed by others
References
Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL . 1999 Mol. Cell. Biol. 19: 5143–5154
Araki S, Haneda M, Togawa M, Kikkawa R . 1997 Kidney Int. 51: 631–639
Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B, Lenardo MJ, Tomaselli KJ, Cohen JI . 1997 Proc. Natl. Acad. Sci. USA 94: 1172–1176
Chen YR, Zhou G, Tan TH . 1999 Mol. Pharmacol. 56: 1271–1279
Chinnaiyan AM, Dixit VM . 1996 Curr. Biol. 6: 555–562
Chow SC, Weis M, Kass GE, Holmstrom TH, Eriksson JE, Orrenius S . 1995 FEBS Lett. 364: 134–138
Clem RJ, Miller LK . 1994 Mol. Cell. Biol. 14: 5212–5222
Day ML, Zhao X, Wu S, Swanson PE, Humphrey PA . 1994 Cell. Growth Differ. 5: 735–741
Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ . 1994 Cell 76: 1025–1037
Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ . 1997 Science 277: 693–696
Ellis RE, Yuan JY, Horvitz HR . 1991 Annu. Rev. Cell. Biol. 7: 663–698
Franklin CC, Kraft AS . 1997 J. Biol. Chem. 272: 16917–16923
Fronsdal K, Engedal N, Saatcioglu F . 2000 Prostate 43: 111–117
Fujii T, Garcia-Bermejo ML, Bernabo JL, Caamano J, Ohba M, Kuroki T, Li L, Yuspa SH, Kazanietz MG . 2000 J. Biol. Chem. 275: 7574–7582
Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA . 1998 J. Biol. Chem. 273: 32608–32613
Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, Fuks Z, Kolesnick R . 1998 Cancer Res. 58: 2260–2264
Gu Y, Sarnecki C, Aldape RA, Livingston DJ, Su MS . 1995 J. Biol. Chem. 270: 18715–18718
Henttu P, Vihko P . 1998 Biochem. Biophys. Res. Commun. 244: 167–171
Hibi M, Lin A, Smeal T, Minden A, Karin M . 1993 Genes Dev. 7: 2135–2148
Hirsch DD, Stork PJ . 1997 J. Biol. Chem. 272: 4568–4575
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP . 1983 Cancer Res. 43: 1809–1818
Huggins C, Hodges CV . 1941 Cancer Res. 1: 293–297
Isaacs JT . 1994 Vitam. Horm. 49: 433–502
Jacobson MD, Weil M, Raff MC . 1997 Cell 88: 347–354
Karin M . 1998 Ann. N.Y. Acad. Sci. 851: 139–146
Kerr JF, Wyllie AH, Currie AR . 1972 Br. J. Cancer 26: 239–257
Kinzel V, Bonheim G, Richards J . 1988 Cancer Res. 48: 1759–1762
Kuroki DW, Bignami GS, Wattenberg EV . 1996 Cancer Res. 56: 637–644
Lenczowski JM, Dominguez L, Eder AM, King LB, Zacharchuk CM, Ashwell JD . 1997 Mol. Cell. Biol. 17: 170–181
Lewis TS, Shapiro PS, Ahn NG . 1998 Adv. Cancer Res. 74: 49–139
Li X, Yu H, Graves LM, Earp HS . 1997 J. Biol. Chem. 272: 14996–15002
Liu ZG, Hsu H, Goeddel DV, Karin M . 1996 Cell 87: 565–576
Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M . 1997 Lab. Invest. 76: 37–51
Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M . 1998 Virchows Arch. 432: 407–413
Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B, Denner L . 1999 Cancer Res. 59: 382–390
McConkey DJ, Greene G, Pettaway CA . 1996 Cancer Res. 56: 5594–5599
Miller LK . 1997 J. Cell Physiol. 173: 178–182
Minden A, Karin M . 1997 Biochim. Biophys. Acta 1333: F85–F104
Minden A, Lin A, Claret FX, Abo A, Karin M . 1995 Cell 81: 1147–1157
Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C . 1998 Urol. Int. 60: Suppl 1 25–29
Moore RA . 1994 Surgery 16: 152–167
Nagahara A, Wang L, Del Valle J, Todisco A . 1998 Am. J. Physiol. 275: G740–G748
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Sayyaparaju MR, Smulson ME, Yamin T-T, Violeta LY, Miller DK . 1995 Nature 376: 37–43
Robinson MJ, Cobb MH . 1997 Curr. Opin. Cell Biol. 9: 180–186
Roulston A, Reinhard C, Amiri P, Williams LT . 1998 J. Biol. Chem. 273: 10232–10239
Shrode LD, Rubie EA, Woodgett JR, Grinstein S . 1997 J. Biol. Chem. 272: 13653–13659
Sluss HK, Barrett T, Derijard B, Davis RJ . 1994 Mol. Cell. Biol. 14: 8376–8384
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW . 1999 Science 284: 156–159
Srivastava RK, Sollott SJ, Khan L, Hansford R, Lakatta EG, Longo DL . 1999 Mol. Cell. Biol. 19: 5659–5674
Stattin P, Westin P, Damber JE, Bergh A . 1998 Br. J. Cancer 77: 670–675
Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben Neriah Y . 1994 Cell 77: 727–736
Treiman M, Caspersen C, Christensen SB . 1998 Trends Pharmacol. Sci. 19: 131–135
Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D . 2000 Science 287: 664–666
Wertz IE, Dixit VM . 2000 J. Biol. Chem. 275: 11470–11477
Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA . 1994 J. Biol. Chem. 269: 26396–26401
White E . 1996 Genes Dev. 10: 1–15
Widmann C, Gibson S, Jarpe MB, Johnson GL . 1999 Physiol. Rev. 79: 143–180
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME . 1995 Science 270: 1326–1331
Yasuda J, Whitmarsh AJ, Cavanagh J, Sharma M, Davis RJ . 1999 Mol. Cell. Biol. 19: 7245–7254
Young CY, Murtha PE, Zhang J . 1994 Oncol. Res. 6: 203–210
Zhang P, Miller BS, Rosenzweig SA, Bhat NR . 1996 J. Neurosci. Res. 46: 114–121
Zhao X, Gschwend JE, Powell CT, Foster RG, Day KC, Day ML . 1997 J. Biol. Chem. 272: 22751–22757
Zhu H, Fearnhead HO, Cohen GM . 1995 FEBS Lett. 374: 303–308
Acknowledgements
We are grateful to Drs JI Cohen, R Davis and M Karin for generous gifts of plasmids. This work was supported by grants from the Norwegian Cancer Society and the University of Oslo to F Saatcioglu.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Engedal, N., Korkmaz, C. & Saatcioglu, F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 21, 1017–1027 (2002). https://doi.org/10.1038/sj.onc.1205167
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205167
Keywords
This article is cited by
-
JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-0-tetradecanoylphorbol-13-acetate (TPA)
British Journal of Cancer (2004)
-
Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2 -terminal kinase signaling pathways in human hepatoma HepG2 cells
British Journal of Pharmacology (2003)
-
Protein kinase CÉ› interacts with Bax and promotes survival of human prostate cancer cells
Oncogene (2003)